Sunday, April 14, 2024
    HomeBusinessOzempic's early success in kidney disease trial drags on dialysis stocks

    Ozempic’s early success in kidney disease trial drags on dialysis stocks

    The outdoor sign seen at the DaVita Dialysis clinic in Denver February 16, 2016. REUTERS/Rick Wilking/File Photo Acquire Licensing Rights

    Oct 11 (Reuters) – Shares of dialysis service providers fell sharply on Wednesday after Novo Nordisk’s (NOVOb.CO) Ozempic showed early signs of success in delaying the progression of kidney disease in diabetes patients.

    Colorado-based DaVita’s (DVA.N) shares fell about 16%, to $76.62, and U.S.-listed shares of German rival Fresenius Medical (FMEG.DE) were down 16.7%, to $17.44, in early trading. Shares of U.S.-based Baxter International (BAX.N), which makes products used by dialysis therapy providers, also fell 5.8%, to $35.14.

    The Danish drugmaker said late on Tuesday it will stop the trial almost a year ahead of schedule based on interim results from the study, which met the pre-set criteria for efficacy according to an independent data monitoring committee.

    The dialysis market has for decades been sustained by high rates of obesity and diabetes, which contribute to kidney damage, but GLP-1 drugs such as Novo’s Ozempic and Wegovy have been seen to dramatically improve both conditions.

    Novo’s announcement is the latest sign of disruption caused by the success of GLP-1 drugs, which have hit the shares of food companies, providers of bariatric surgery and companies that make glucose-monitoring devices.

    The new data is the “latest piece of positive news” for GLP-1 drugs and continues its clinical advancements, said Wells Fargo analyst Mohit Bansal, adding that success in kidney-disease patients could unlock a population of as many as 5 million patients for such medication.

    Citi analysts said GLP-1 drugs could shrink the size of the eligible dialysis population over time.

    Frankfurt-listed shares of Fresenius fell 7.7%, to 25.52 euros ($27.09).

    DaVita’s price-to-earnings ratio for the next 12 months, a common benchmark for valuing stocks, stood at 11.91, compared with Fresenius Medical’s 14.30.

    Including session moves, U.S.-listed shares of Fresenius were up about 7%, DaVita’s shares rose by about 2%, while Baxter’s shares were down around 31% so far this year.

    ($1 = 0.9434 euros)

    Reporting by Mariam Sunny in Bengaluru; Editing by Janane Venkatraman and Pooja Desai

    Our Standards: The Thomson Reuters Trust Principles.

    Acquire Licensing Rights, opens new tab


    Please enter your comment!
    Please enter your name here

    - Advertisment -
    Google search engine

    Most Popular

    Recent Comments